‘Pfizer India will choke on Corex ban’

Updated - December 04, 2021 11:34 pm IST

Published - March 14, 2016 06:52 pm IST - MUMBAI

The Pfizer logo is displayed at world headquarters, Monday, Nov. 23, 2015, in New York. Pfizer and Allergan will join in a $160 billion deal to create the world's largest drugmaker. (AP Photo/Mark Lennihan)

The Pfizer logo is displayed at world headquarters, Monday, Nov. 23, 2015, in New York. Pfizer and Allergan will join in a $160 billion deal to create the world's largest drugmaker. (AP Photo/Mark Lennihan)

The ban on cough syrup Corex by the government among 350 other drugs will hit Pfizer India hard, the Indian arm of the U.S. pharmaceutical giant Pfizer said on Monday.

Reacting to the ban, which was announced last week, Pfizer India stock plummeted 9 per cent and finally closed with a loss of 8.67 per cent at Rs 1,760.80 on the BSE.

The Ministry of Health had on March 10, 2016, prohibited the manufacture, sale and distribution of 350 fixed dose combinations over safety concerns. The ban will impact Pfizer’s brand Corex, the company said.

“The above prohibition is likely to have an adverse impact on the revenue and profitability of the company. It may be noted that Corex recorded a sale of Rs 176 crore for the nine months period ended December 31, 2015.”

According to AIOCD Pharmasofttech AWACS Pvt. Ltd, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors Ltd, Pfizer India will bear a pact of Rs 368 crore on account of the ban, which is nearly 13 per cent of its revenues.

“In view of this (ban) the company has discontinued the manufacture and sale of Corex with immediate effect. Corex has a well-established efficacy and safety profile in India for more than 30 years and Pfizer makes every effort to maintain the highest standards of regulatory and quality compliance in the manufacture and distribution of Corex,” Pfizer said in a filing to the stock exchange.

“The company is exploring all available options at its disposal,” it added.

According to reports, Pfizer India on Monday moved the Delhi High Court challenging the ban and the court has stayed the government’s order.

A Pfizer spokesperson could not be reached for confirmation and comment.

AIOCD Pharmasofttech AWACS said other brands that will bear the brunt of the ban include Phensedyl of Abbott India and Panderm Plus of Macleods Pharma. These two companies will witness an adverse impact of Rs 485 crore and Rs 370 crore due to the ban. Their revenue will be eroded by 15.39 per cent and 13.07 per cent, the research firm said.

Abbott India stock closed with a loss of 0.68 per cent at Rs 4,884 on the BSE.

The Indian pharma companies that will see their revenue depleting due to this ban include Mankind Pharma, Alkem, Ipca, Glenmark and Wockhardt.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.